March 2018 Default Cover Image
Ustekinumab shows promise for reducing psoriasis-associated cardiovascular comorbidityInitial results of an investigator-initiated phase 4 trial suggest that blocking interleukin-12 (IL-12) and IL-23 may reduce cardiovascular inflammation associated with psoriasis, researchers reported at AAD 2018.
From new vaccines to the advent of new neurotoxinsPhysicians weigh in expectations for new developments within all facets of dermatology from pediatric dermatology to dermatopathology.
Stem cell transplant offers long-term hope for severe scleroderma patientsAn intensive stem cell transplant regimen achieved better survival as compared to cyclophosphamide treatment for patients with severe scleroderma, researchers report in the New England Journal of Medicine.
Combination treatment for scars proves effectiveCombination treatments to reduce scarring have been shown to be effective without the need for aggressive surgical techniques that can lead to suboptimal results, researchers reported at AAD 2018 this week.
Insights to improve your psoriasis care planKnowledge of outcomes data, adverse events may help physicians formulate effective treatment strategies, Dr. April Armstrong says.